Sotera Health Announces Secondary Offering of Common Stock

Rhea-AI Summary

Sotera Health (Nasdaq: SHC) announced a secondary offering of 25 million common shares on March 4, 2026. All shares are being sold by affiliates of Warburg Pincus and GTCR; the company is not selling shares and will not receive proceeds.

Wells Fargo Securities is the underwriter; the company will pay offering expenses under its registration rights agreement. The offering will be made only by prospectus and a registration statement filed February 27, 2024, became effective automatically.

Positive

• 25 million shares offered by selling stockholders
• Offering increases public float and market liquidity

Negative

• Company will not receive any proceeds from the Offering
• Company will pay the Offering expenses under its agreement

News Market Reaction – SHC

-4.44%

4 alerts

-4.44% Session close to close

$4.48B Market Cap

0.0x Rel. Volume

In the Mar 5 session, SHC declined 4.44%, reflecting a moderate negative market reaction. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details a sponsor-led secondary of 25,000,000 existing shares, with Sotera Health ...

Analysis

This announcement details a sponsor-led secondary of 25,000,000 existing shares, with Sotera Health itself not issuing stock and receiving no proceeds. The company will cover offering expenses under its registration rights agreement, and Wells Fargo Securities will underwrite sales across Nasdaq and other venues. Historically, similar offerings have produced mixed share-price reactions, so investors may focus on whether ownership shifts affect trading dynamics or governance over time.

Key Figures

Secondary shares offered: 25,000,000 shares Par value per share: $0.01 per share Registration statement date: February 27, 2024 +1 more

4 metrics

Secondary shares offered 25,000,000 shares Shares of common stock offered by Warburg Pincus and GTCR affiliates

Par value per share $0.01 per share Par value of Sotera Health common stock

Registration statement date February 27, 2024 SEC registration statement filing date for these securities

Underwriter phone 800-645-3751 Wells Fargo Securities contact for preliminary prospectus

Previous Offering Reports

2 past events · Latest: Nov 06 (Neutral)

Same Type Pattern 2 events

Date	Event	Sentiment	24h Move	Catalyst
Nov 06	Secondary offering	Neutral	-2.1%	Sponsors sold 30,000,000 shares; company received no offering proceeds.
Sep 04	Secondary offering	Neutral	+6.9%	Sponsors sold 25,000,000 shares and relinquished majority ownership.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Prior secondary offerings by sponsors produced mixed reactions, with one modest decline and one mid-single-digit gain, averaging a 2.44% move.

Recent Company History

Recent tagged events show Sotera’s sponsors repeatedly using secondary offerings to sell blocks of shares, with the company itself not receiving proceeds. On 2025-11-06, a 30,000,000-share secondary by Warburg Pincus and GTCR led to a -2.06% move. A prior 25,000,000-share secondary on 2024-09-04 coincided with a 6.94% gain. Today’s offering continues this pattern of sponsor-driven liquidity transactions.

Key Terms

secondary offering, prospectus, registration statement, Securities and Exchange Commission, +1 more

5 terms

secondary offering financial

"today announced the launch of a secondary offering (the “Offering”) of 25 million shares"

A secondary offering is when a company sells new shares of its stock to the public after its initial sale. This allows existing shareholders or the company itself to raise additional money. For investors, it can impact the stock’s price by increasing the total number of shares available, which may influence the stock’s value and how the market perceives the company’s financial health.

View in glossary

prospectus regulatory

"The Offering is being made only by means of a prospectus."

A prospectus is a detailed document that explains a company's plans for offering new shares or investments to the public. It’s important because it provides potential investors with key information about the company’s business, risks, and how they might make money, helping them decide whether to invest. Think of it as a guidebook for understanding what you're buying into.

registration statement regulatory

"A registration statement relating to these securities was filed with the Securities"

A registration statement is a formal document that companies file with a government agency to offer new shares of stock to the public. It provides essential information about the company's finances, operations, and risks, helping investors make informed decisions. Think of it as a detailed product description that ensures transparency and trust before buying into a company.

Securities and Exchange Commission regulatory

"was filed with the Securities and Exchange Commission on February 27, 2024,"

A national government agency that enforces rules for buying, selling and disclosing information about stocks and other investments, acting like a referee and scorekeeper for financial markets. It requires companies to share clear, regular financial and business information and investigates fraud or rule-breaking, which matters to investors because those rules and disclosures help ensure fair prices, reduce hidden risks and make it easier to compare investment choices.

over-the-counter market financial

"on Nasdaq, in the over-the-counter market or through negotiated transactions"

A market where securities are bought and sold directly between dealers and brokers instead of on a centralized stock exchange. Think of it like a neighborhood bazaar compared with a big supermarket: prices and rules can vary, oversight is lighter, and some instruments are harder to trade or riskier. Investors care because OTC listings can offer access to small or specialized investments but often come with higher price volatility, lower liquidity, and greater information risk.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CLEVELAND, March 04, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC) (the “Company”) today announced the launch of a secondary offering (the “Offering”) of 25 million shares of its common stock, par value $0.01 per share. All 25 million shares are being offered for sale by certain affiliates of Warburg Pincus LLC (“Warburg Pincus”) and GTCR LLC (“GTCR”) as selling stockholders. No other entities, and no individuals, are selling shares in the Offering. The Company is not offering any shares in the Offering and will not receive any of the proceeds from the Offering. The Company will pay the expenses of the Offering pursuant to its obligations under its Amended and Restated Registration Rights Agreement.

Wells Fargo Securities is acting as the underwriter for the Offering. The underwriter will offer the shares from time to time in one or more transactions on Nasdaq, in the over-the-counter market or through negotiated transactions at market prices or at negotiated prices.

The Offering is being made only by means of a prospectus. Copies of the preliminary prospectus relating to the Offering may be obtained, when available, from: Wells Fargo Securities, LLC, 90 South 7th Street, 5th Floor, Minneapolis, MN 55402, by telephone at (800)-645-3751 (option #5) or by email at WFScustomerservice@wellsfargo.com.

A registration statement relating to these securities was filed with the Securities and Exchange Commission on February 27, 2024, and became effective automatically.

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy these securities, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Forward-looking Statements:

Statements in this press release regarding the Company that are not historical facts are “forward-looking statements” that involve risks and uncertainties. Certain of these risks and uncertainties are described in the Company’s registration statement on Form S-3 filed with the SEC, including under the headings “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements,” under the headings “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Company’s most recent Annual Report on Form 10-K. Forward-looking statements made in this release speak only as of the date of this release, and the Company undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances, except as required by law.

About Sotera Health:

Sotera Health Company is a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry. Sotera Health goes to market through three businesses – Sterigenics®, Nordion® and Nelson Labs®. Sotera Health is committed to its mission, Safeguarding Global Health®.

INVESTOR RELATIONS CONTACT:

Jason Peterson
Vice President, Investor Relations, Sotera Health
IR@soterahealth.com 

MEDIA CONTACT:

Kristin Gibbs
Chief Marketing Officer, Sotera Health
kgibbs@soterahealth.com

Source: Sotera Health Company

FAQ

What is Sotera Health (SHC) selling in the March 4, 2026 secondary offering?

The offering is for 25 million common shares sold by Warburg Pincus and GTCR affiliates. According to the company, all shares are being sold by those selling stockholders and no company shares are included.

Will the March 4, 2026 SHC secondary offering dilute existing shareholders?

No, the company said the Offering does not include company‑sold shares and will not raise proceeds for Sotera Health. The sale is by existing shareholders, which does not create new shares issued by the company.

Who is acting as underwriter for the SHC secondary offering and how will shares be sold?

Wells Fargo Securities is the underwriter for the Offering. According to the company, shares may be offered on Nasdaq, over‑the‑counter, or through negotiated transactions at market or negotiated prices.

Will Sotera Health receive proceeds from the 25 million share offering (SHC)?

No, Sotera Health will not receive any proceeds from the Offering. According to the company, the entire 25 million shares are being sold by Warburg Pincus and GTCR affiliates.

How can investors obtain the SHC prospectus for the March 4, 2026 offering?

Investors can request the preliminary prospectus from Wells Fargo Securities by phone or email. According to the company, copies will be available when the prospectus is available from the underwriter.